The effects of insulin treatment on hepatic parameters in diabetic animal models of NAFLD/NASH have been examined in a few preclinical studies and these studies report varying effects of insulin treatment on hepatic inflammation and fibrosis [24–27]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.